医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Notification of a New Drug Application for HP-3070 (Transdermal Patch for the Treatment of Schizophrenia) in the U.S.

2018年12月17日 PM11:00
このエントリーをはてなブックマークに追加


 

MIAMI

Hisamitsu Pharmaceutical Co., Ltd. (Headquarters: Tosu City, Saga Prefecture, President and Chief Executive Officer (CEO): Hirotaka Nakatomi, hereinafter “Hisamitsu Pharmaceutical”), in conjunction with its U.S. subsidiary, Noven Pharmaceuticals, Inc., announces that a New Drug Application has been submitted to the U.S. Food and Drug Administration (FDA) seeking approval of HP-3070 (asenapine) transdermal system for the treatment of schizophrenia (Development code: HP-3070, generic name: asenapine, hereinafter referred to as “the investigational product”).

The investigational product is a systemic transdermal formulation developed using Hisamitsu Pharmaceutical’s Transdermal Drug Delivery System (TDDS) technology. Hisamitsu Pharmaceutical expects the investigational product to be a new option in the treatment of schizophrenia. The development of the investigational product represents Hisamitsu Pharmaceutical’s commitment to improving the lives of the community of patients who live with schizophrenia.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181217005053/en/

CONTACT

Stephanie Lamenta
Noven Pharmaceuticals
305-253-1916

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 韓国スキンケアブランド「Dear, Klairs(クレアス)」が、日本限定版の「ビタミンライン2種 桜エディション」で春の訪れをいち早くお届けします
  • U.S. FDA Approves Takeda’s TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older
  • GPHC: Good Start but Accountability Gap Undermines Potential of Pandemic Treaty
  • Exscientia宣布对百时美施贵宝许可的PKC Theta抑制剂EXS4318进行首次人体研究
  • Bruker Announces Successful Customer Installations of First Two Compact 1.0 GHz NMR Systems to Advance Structural Biology